Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer

Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors

(2022) Saiama N. Waqar et al.   INVESTIGATIONAL NEW DRUGS

Cell cycle involvement in cancer therapy; WEE1 kinase, a potential target as therapeutic strategy

(2022) Sajjad Vakili-Samiani et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1

(2022) Amirali B. Bukhari et al.   Frontiers in Oncology

Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer

(2022) Mary Smithson et al.   NEOPLASIA

Cancer treatment and survivorship statistics, 2022

(2022) Kimberly D. Miller et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Sustained CHK2 activity, but not ATM activity, is critical to maintain a G1 arrest after DNA damage in untransformed cells

(2021) Iraia García-Santisteban et al.   BMC BIOLOGY

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors

(2021) Yipeng Song et al.   Frontiers in Oncology

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours

(2021) Mark R. Middleton et al.   BRITISH JOURNAL OF CANCER

Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours

(2021) Geoffrey I. Shapiro et al.   BRITISH JOURNAL OF CANCER

Activation of CDC25A phosphatase is limited by CDK2/cyclin A-mediated feedback inhibition

(2021) Jennifer P. Ditano et al.   CELL CYCLE

ATM’s Role in the Repair of DNA Double-Strand Breaks

(2021) Atsushi Shibata et al.   Genes

DNA Damage Repair Inhibitors—Combination Therapies

(2021) Gabriella Smith et al.   CANCER JOURNAL

Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring

(2021) Jenny F. Seligmann et al.   JOURNAL OF CLINICAL ONCOLOGY

WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry

(2020) Camilla R. Elbæk et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

Replication Stress, DNA Damage, Inflammatory Cytokines and Innate Immune Response

(2020) Sandrine Ragu et al.   Genes

CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication

(2020) Sabrina Florencia Mansilla et al.   Genes

ATM-Deficient Cancers Provide New Opportunities for Precision Oncology

(2020) Nicholas R. Jette et al.   Cancers

The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review

(2020) Kai Liu et al.   Cancer Cell International

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

(2020) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target

(2020) Andrea Ghelli Luserna di Rorà et al.   Journal of Hematology & Oncology

Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy

(2020) Juyan Zheng et al.   Molecular Cancer

Integrating Old and New Paradigms of G1/S Control

(2020) Seth M. Rubin et al.   MOLECULAR CELL

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials

(2020) Willemijn S M E Theelen et al.   Lancet Respiratory Medicine

Reality CHEK: Understanding the biology and clinical potential of CHK1

(2020) Fiifi Neizer-Ashun et al.   CANCER LETTERS

The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors

(2020) Linda van Bijsterveldt et al.   CLINICAL CANCER RESEARCH

The Impact of Radiation-Induced DNA Damage on cGAS-STING-Mediated Immune Responses to Cancer

(2020) Quinn Storozynsky et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting immunogenic cell death in cancer

(2020) Asma Ahmed et al.   Molecular Oncology

DNA-PKcs: A Multi-Faceted Player in DNA Damage Response

(2020) Xiaoqiao Yue et al.   Frontiers in Genetics

Modeling the interplay between DNA-PK, Artemis, and ATM in non-homologous end-joining repair in G1 phase of the cell cycle

(2019) Maryam Rouhani   JOURNAL OF BIOLOGICAL PHYSICS

Radiation-induced DNA damage response and resistance in colorectal cancer stem-like cells

(2019) Kumari Anuja et al.   INTERNATIONAL JOURNAL OF RADIATION BIOLOGY

A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.

(2019) Elizabeth Ruth Plummer et al.   JOURNAL OF CLINICAL ONCOLOGY

Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage

(2019) Sara Giovannini et al.   NUCLEIC ACIDS RESEARCH

Cancer Stem Cells and Radioresistance: DNA Repair and Beyond

(2019) Alexander Schulz et al.   Cancers

Activation of ATR-related protein kinase upon DNA damage recognition

(2019) Minh Ma et al.   CURRENT GENETICS

A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer

(2019) Johanna C. Bendell et al.   INVESTIGATIONAL NEW DRUGS

Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy

(2019) Catherine E. Willoughby et al.   JOURNAL OF CLINICAL INVESTIGATION

Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer

(2019) Kyle C. Cuneo et al.   JOURNAL OF CLINICAL ONCOLOGY

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

(2019) Jacqueline H. L. Fok et al.   Nature Communications

Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting

(2019) Julian Biau et al.   Frontiers in Oncology

A potential new role of ATM inhibitor in radiotherapy: suppressing ionizing Radiation-Activated EGFR

(2019) Siyuan Tang et al.   INTERNATIONAL JOURNAL OF RADIATION BIOLOGY

Inhibition of MELK produces potential anti‐tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway

(2019) Song Chen et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers

(2019) Tatiana Kamaletdinova et al.   Cells

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors

(2018) A Italiano et al.   ANNALS OF ONCOLOGY

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

(2018) Jordan Berlin et al.   BRITISH JOURNAL OF CANCER

A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer

(2018) Michael J. Pishvaian et al.   CANCER

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

(2018) Lorenzo Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

(2018) Andrea Cercek et al.   JAMA Oncology

ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation

(2018) Frank P. Vendetti et al.   JOURNAL OF CLINICAL INVESTIGATION

OUP accepted manuscript

(2018)   JNCI-Journal of the National Cancer Institute

Membrane receptor signaling and control of DNA repair after exposure to ionizing radiation

(2018) M. Toulany et al.   NUKLEARMEDIZIN-NUCLEAR MEDICINE

An intrinsic S/G2 checkpoint enforced by ATR

(2018) Joshua C. Saldivar et al.   SCIENCE

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

(2018) Vera Gorbunova et al.   BRITISH JOURNAL OF CANCER

Clinical Development of Novel Drug–Radiotherapy Combinations

(2018) Saif S. Ahmad et al.   CLINICAL CANCER RESEARCH

CDC25A pathway toward tumorigenesis: Molecular targets of CDC25A in cell-cycle regulation

(2018) Hossein Sadeghi et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

State-of-the-art strategies for targeting the DNA damage response in cancer

(2018) Patrick G. Pilié et al.   Nature Reviews Clinical Oncology

Homologous Recombination and the Formation of Complex Genomic Rearrangements

(2018) Aurèle Piazza et al.   TRENDS IN CELL BIOLOGY

CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells

(2017) Gwenola Manic et al.   GUT

Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan

(2017) Yunping Yin et al.   Molecular Medicine Reports

Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases

(2017) et al.   MOLECULES

Synthetic lethality and cancer

(2017) Nigel J. O'Neil et al.   NATURE REVIEWS GENETICS

The essential kinase ATR: ensuring faithful duplication of a challenging genome

(2017) Joshua C. Saldivar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Non-homologous DNA end joining and alternative pathways to double-strand break repair

(2017) Howard H. Y. Chang et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

G9a governs colon cancer stem cell phenotype and chemoradioresistance through PP2A-RPA axis-mediated DNA damage response

(2017) Chi-Wen Luo et al.   RADIOTHERAPY AND ONCOLOGY

DNA Damage and Repair Biomarkers of Immunotherapy Response

(2017) Kent W. Mouw et al.   Cancer Discovery

Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2

(2017) Britta Vormoor et al.   Oncotarget

Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases—Implications for Intraoperative Radiotherapy after Resection

(2017) Carsten Herskind et al.   Frontiers in Oncology

Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.

(2017) A. L. Ho et al.   JOURNAL OF CLINICAL ONCOLOGY

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

(2016) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells

(2016) Takahisa Hirai et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

(2016) T.A. Yap et al.   EUROPEAN JOURNAL OF CANCER

Global patterns and trends in colorectal cancer incidence and mortality

(2016) Melina Arnold et al.   GUT

Low-dose irradiation promotes proliferation of the human breast cancer MDA-MB-231 cells through accumulation of mutant P53

(2016) Si-Jie Li et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187

(2016) Eric X. Chen et al.   INVESTIGATIONAL NEW DRUGS

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer

(2016) David Hong et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

(2016) Suzanne Leijen et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors

(2016) Fei Huang et al.   NUCLEIC ACIDS RESEARCH

Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer

(2016) L. Leichman et al.   ONCOLOGIST

Structure of the intact ATM/Tel1 kinase

(2016) Xuejuan Wang et al.   Nature Communications

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors

(2016) Jessica S. Brown et al.   Cancer Discovery

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells

(2015) M. Kwok et al.   BLOOD

Connecting the microtubule attachment status of each kinetochore to cell cycle arrest through the spindle assembly checkpoint

(2015) P. Todd Stukenberg et al.   CHROMOSOMA

Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways

(2015) M. A. Morgan et al.   CLINICAL CANCER RESEARCH

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

(2015) Khanh Do et al.   JOURNAL OF CLINICAL ONCOLOGY

Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway

(2015) Marwan Kwok et al.   LANCET

YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors

(2015) G. C. Stachelek et al.   MOLECULAR CANCER RESEARCH

Alternative end-joining repair pathways are the ultimate backup for abrogated classical non-homologous end-joining and homologous recombination repair: Implications for the formation of chromosome translocations

(2015) George Iliakis et al.   MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS

The fork and the kinase: A DNA replication tale from a CHK1 perspective

(2015) Marina A. González Besteiro et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

ATM and ATR as therapeutic targets in cancer

(2015) Anika Maria Weber et al.   PHARMACOLOGY & THERAPEUTICS

PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair

(2015) T. Ochi et al.   SCIENCE

Radiotherapy and Immunogenic Cell Death

(2015) Encouse B. Golden et al.   SEMINARS IN RADIATION ONCOLOGY

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

(2014) Edward Sausville et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Poly(ADP-ribose) polymerases in double-strand break repair: Focus on PARP1, PARP2 and PARP3

(2014) Carole Beck et al.   EXPERIMENTAL CELL RESEARCH

Alterations of cell cycle control proteins SHP-1/2, p16, CDK4 and cyclin D1 in radioresistant nasopharyngeal carcinoma cells

(2014) GANG PENG et al.   Molecular Medicine Reports

Downregulated Ku70 and ATM associated to poor prognosis in colorectal cancer among Chinese patients

(2014) Yuanming Lu et al.   OncoTargets and Therapy

CHK2 kinase in the DNA damage response and beyond

(2014) L. Zannini et al.   Journal of Molecular Cell Biology

Ionizing Radiation-Induced DNA Damage, Response, and Repair

(2013) Wil L. Santivasi et al.   ANTIOXIDANTS & REDOX SIGNALING

Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours

(2013) Takashi Seto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies

(2013) Thomas P Matthews et al.   Expert Opinion on Drug Discovery

In Vitro and In Vivo Enhancement of Chemoradiation Using the Oral PARP Inhibitor ABT-888 in Colorectal Cancer Cells

(2013) Joseph W. Shelton et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer

(2013) M. A. Batey et al.   MOLECULAR CANCER THERAPEUTICS

Comparative Analysis of Radiosensitizers for K-RAS Mutant Rectal Cancers

(2013) Laura B. Kleiman et al.   PLoS One

PCNA is efficiently loaded on the DNA recombination intermediate to modulate polymerase  ,  , and   activities

(2013) J. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DNA Damage Sensing by the ATM and ATR Kinases

(2013) A. Marechal et al.   Cold Spring Harbor Perspectives in Biology

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition

(2012) I M Pires et al.   BRITISH JOURNAL OF CANCER

Mechanisms of replication fork protection: a safeguard for genome stability

(2012) Alessia Errico et al.   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

Identification and Characterization of a Small Inhibitory Peptide That Can Target DNA-PKcs Autophosphorylation and Increase Tumor Radiosensitivity

(2012) Xiaonan Sun et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

The combination of olaparib and camptothecin for effective radiosensitization

(2012) Katsutoshi Miura et al.   Radiation Oncology

Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1

(2012) Marieke Aarts et al.   Cancer Discovery

Radiation as an immunological adjuvant: current evidence on dose and fractionation

(2012) Sandra Demaria et al.   Frontiers in Oncology

Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer

(2011) Prapti A. Patel   ANTI-CANCER DRUGS

The role of PARP in DNA repair and its therapeutic exploitation

(2011) M Javle et al.   BRITISH JOURNAL OF CANCER

Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

(2011) S. Kummar et al.   CANCER RESEARCH

MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells

(2011) K. A. Bridges et al.   CLINICAL CANCER RESEARCH

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

(2011) Jens Samol et al.   INVESTIGATIONAL NEW DRUGS

Regulation of MDM2 E3 Ligase Activity by Phosphorylation after DNA Damage

(2011) Q. Cheng et al.   MOLECULAR AND CELLULAR BIOLOGY

The role of homologous recombination in radiation-induced double-strand break repair

(2011) Penny A. Jeggo et al.   RADIOTHERAPY AND ONCOLOGY

Combination of quercetin with radiotherapy enhances tumor radiosensitivity in vitro and in vivo

(2011) Chenghe Lin et al.   RADIOTHERAPY AND ONCOLOGY

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

(2010) Hiroshi Hirai et al.   CANCER BIOLOGY & THERAPY

In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma

(2010) Shahryar E. Mir et al.   CANCER CELL

Radiosensitization by Chir-124, a selective Chk1 inhibitor: Effects of p53 and cell cycle checkpoints

(2010) Yungan Tao et al.   CELL CYCLE

Mechanism of p53 stabilization by ATM after DNA damage

(2010) Qian Cheng et al.   CELL CYCLE

In vitro and In vivo Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor, AZD7762

(2010) J. B. Mitchell et al.   CLINICAL CANCER RESEARCH

Phosphorylation of Mcl-1 by CDK1–cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest

(2010) Margaret E Harley et al.   EMBO JOURNAL

ATR: a master conductor of cellular responses to DNA replication stress

(2010) Rachel Litman Flynn et al.   TRENDS IN BIOCHEMICAL SCIENCES

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Limited terminal transferase in human DNA polymerase   defines the required balance between accuracy and efficiency in NHEJ

(2009) P. Andrade et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA